Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 0 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 0 25 versus THYROLAR 0 5.
THYROLAR-0.25 vs THYROLAR-0.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyroid hormone (liothyronine, L-triiodothyronine or T3) binds to thyroid hormone receptors in the nucleus, altering gene transcription and protein synthesis, leading to increased metabolic rate, oxygen consumption, and thermogenesis.
Thyroid hormone replacement; L-thyroxine (T4) is converted to active triiodothyronine (T3) which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate and oxygen consumption.
Oral, 0.25 mg (1 tablet) once daily; adjust based on TSH response.
Initial dose 0.5 tablets (30 mg T4/7.5 mg T3) orally once daily, titrated every 2-4 weeks based on TSH, free T4, and free T3 levels; usual maintenance 0.5-2 tablets (30-120 mg T4/7.5-30 mg T3) once daily.
None Documented
None Documented
Levothyroxine (T4): ~7 days; liothyronine (T3): ~1 day. Clinical context: Steady-state achieved in ~5 weeks for T4; T3 half-life shorter leads to more frequent dosing if used alone.
For liothyronine (T3): approximately 1.5-2.5 days; for levothyroxine (T4): approximately 6-7 days. In hyperthyroidism, half-life may be shortened; in hypothyroidism, prolonged.
Renal: ~40% as conjugated metabolites (glucuronides and sulfates); fecal: ~20% via bile; minor biliary elimination of parent drug (<5%). Total renal clearance of iodine: ~30%.
Renal (approximately 40-50% as unchanged drug and conjugates), fecal (approximately 20-30% via biliary elimination), with the remainder metabolized and eliminated via urine and feces.
Category C
Category C
Thyroid Hormone
Thyroid Hormone